MiNK Therapeutics (INKT) Cash from Investing Activities (2021 - 2023)
MiNK Therapeutics (INKT) posted Cash from Investing Activities of -$23043.0 for Q3 2023, up 37.75% sequentially from -$37018.0 in Q2 2023, and up 61.46% YoY from -$14271.4 in Q3 2022.
MiNK Therapeutics (INKT) Cash from Investing Activities (2021 - 2023) Analysis & Trends
MiNK Therapeutics has reported Cash from Investing Activities for 3 years, with the latest figure at -$23043.0 in Q3 2023.
- Quarterly Cash from Investing Activities rose 61.46% year-over-year to -$23043.0 in Q3 2023, while the trailing twelve-month figure through Dec 2023 was -$73561.0 (up 75.41% YoY) and the FY2023 annual result came in at -$73561.0, up 70.58% from the prior year.
- Cash from Investing Activities improved to -$23043.0 in Q3 2023 per INKT's latest filing, from -$37018.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $277.0 in Q4 2021 and troughed at -$127838.0 in Q4 2022.
- A 3-year average of -$56686.3 and a median of -$39520.0 in 2021 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities sank 46250.9% in 2022, then surged 61.46% in 2023.
- Over 3 years, Cash from Investing Activities stood at $277.0 in 2021, then tumbled by 46250.9% to -$127838.0 in 2022, then surged by 81.97% to -$23043.0 in 2023.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$23043.0, -$37018.0, and -$13500.0 for Q3 2023, Q2 2023, and Q1 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | MiNK Therapeutics | 60.53 Mn | 60.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -23,043.00 |
| Sep 30, 2023 | -23,043.00 |
| Jun 30, 2023 | -37,018.00 |
| Jun 30, 2023 | -37,018.00 |
| Mar 31, 2023 | -13,500.00 |
| Mar 31, 2023 | -13,500.00 |
| Dec 31, 2022 | -127,838.00 |
| Dec 31, 2022 | -127,838.00 |
| Sep 30, 2022 | -59,795.00 |
| Sep 30, 2022 | -59,795.00 |
| Dec 31, 2021 | 277.00 |
| Dec 31, 2021 | 277.00 |
| Sep 30, 2021 | -111,820.00 |
| Sep 30, 2021 | -111,820.00 |
| Jun 30, 2021 | -97,920.00 |
| Jun 30, 2021 | -97,920.00 |
| Mar 31, 2021 | -39,520.00 |
| Mar 31, 2021 | -39,520.00 |